A Human-Centered AI Framework for Efficient Labelling of ECGs From Drug Safety Trials.

Drug safety trials require substantial ECG labelling like, in thorough QT studies, measurements of the QT interval, whose prolongation is a biomarker of proarrhythmic risk. The traditional method of manually measuring the QT interval is time-consuming and error-prone. Studies have demonstrated the potential of deep learning (DL)-based methods to automate this task but expert validation of these computerized measurements remains of paramount importance, particularly for abnormal ECG recordings.

AI-Assisted QT Measurements for Highly Automated Drug Safety Studies.

Rate-corrected QT interval (QTc) prolongation has been suggested as a biomarker for the risk of drug-induced torsades de pointes, and is therefore monitored during clinical trials for the assessment of drug safety. Manual QT measurements by expert ECG analysts are expensive, laborious and prone to errors. Wavelet-based delineators and other automatic methods do not generalize well to different T wave morphologies and may require laborious tuning.

Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome.

Aims: Congenital long-QT syndromes (cLQTS) or drug-induced long-QT syndromes (diLQTS) can cause torsade de pointes (TdP), a life-threatening ventricular arrhythmia. The current strategy for the identification of drugs at the high risk of TdP relies on measuring the QT interval corrected for heart rate (QTc) on the electrocardiogram (ECG). However, QTc has a low positive predictive value.